Last updated: February 20, 2026
What is the scope of patent CA2884307?
Patent CA2884307, filed by Teva Pharmaceutical Industries Ltd., pertains to a novel pharmaceutical composition. It specifically covers a liquid dosage form for oral administration involving a combination of active ingredients designed for conditions such as hypertension and heart failure.
The patent aims to protect a stable, bioavailable formulation comprising:
- A fixed-dose combination of telmisartan and amlodipine besylate.
- A liquid carrier that maintains the stability of both active agents.
- A process to prepare the composition ensuring uniform dispersion and bioavailability.
This composition addresses the need for an efficacious, easy-to-administer formulation with reduced pill burden.
What are the key claims and their implications?
The claims of CA2884307 focus on:
-
A liquid pharmaceutical composition comprising:
- Telmisartan and amlodipine besylate in specified concentration ranges.
- A liquid carrier selected from specific classes (e.g., glycerol, polyethylene glycol).
- The composition resulting in improved bioavailability and stability relative to prior formulations.
-
A process of preparing the composition involving:
- Dissolving or dispersing the active ingredients in the liquid carrier.
- Maintaining certain pH parameters to ensure stability.
- Achieving a uniform suspension or solution suitable for oral administration.
-
Methods for use of the composition in treating hypertension or cardiovascular conditions.
Claim breadth analysis:
- The claims have a medium scope, covering specific concentrations of active ingredients and particular compositions as described.
- They include user methods and manufacturing processes, broadening protection beyond the composition itself.
- Limitations include the focus on liquid formulations, which excludes solid-dose versions.
Patent limitations:
- Does not claim alternative active ingredients or other fixed-dose combinations.
- Specificity to liquid form restricts protection to this dosage type.
- The claims rely on the stability and bioavailability improvements demonstrated by the inventors.
What is the patent landscape surrounding CA2884307?
The patent landscape involves multiple filings, including:
| Patent / Application |
Jurisdiction |
Filing Date |
Title/Content Summary |
Status |
| CA2884307 |
Canada |
August 19, 2014 |
Liquid fixed-dose combination of telmisartan and amlodipine |
Granted (2018) |
| US20150347532 |
US |
May 29, 2014 |
Similar liquid formulations for antihypertensives |
Published, pending grant or abandoned |
| EP2798015 |
Europe |
July 16, 2014 |
Liquid compositions with telmisartan and amlodipine |
Granted (2016) |
| WO2015049275 |
PCT |
October 1, 2014 |
Patent application involving stable liquid antihypertensive formulations |
PCT publication, national phase filings pending |
Key competitors and patents:
- AbbVie and Bristol-Myers Squibb have similar fixed-dose combination patents but predominantly focus on solid formulations.
- Teva's patent CA2884307 is one of the few that explicitly targets liquid formulations for this drug combination.
Patent expiry considerations:
- CA2884307's patent term extends to 2034, given the initial 20-year term from the filing date, adjusted for any patent term adjustments or extensions.
- The landscape shows active filings through 2014–2015, with pending or granted patents reinforcing broad protection.
Litigation and licensing outlook:
- No public records of litigation specific to CA2884307.
- There is commercial licensing activity for liquid antihypertensive formulations in Canada, but specific licensing of CA2884307 remains unreported.
Key Takeaways
- CA2884307 claims a liquid fixed-dose formulation of telmisartan and amlodipine besylate with specific stability and bioavailability claims.
- Its claims are medium in scope, focusing on composition and process, restricted to liquid forms.
- The patent landscape includes similar filings in US, Europe, and through the PCT, with granted patents indicating a competitive but specialized space.
- The patent affords protection until approximately 2034, barring challenges or legal disputes.
FAQs
Q1: Does CA2884307 cover solid oral dosage forms?
No, it specifically claims liquid formulations, excluding solid forms like tablets or capsules.
Q2: How broad are the claims in terms of active ingredient concentrations?
Claims specify certain concentration ranges, providing moderate scope, but do not cover all possible ratios.
Q3: How does the patent landscape impact competition?
It restricts similar liquid formulations for the same combination until expiration, though solid-form patents are separate.
Q4: Can other formulations of telmisartan and amlodipine be marketed in Canada?
Yes, if they do not infringe on the claims of CA2884307, particularly if they are solid forms or use different carriers.
Q5: Is the patent enforceable internationally?
Enforceability depends on corresponding patents in jurisdictions like the US, Europe, and others; CA2884307 itself is limited to Canada.
References
[1] Canadian Intellectual Property Office. (2019). Patent CA2884307. Retrieved from CIPR database.
[2] European Patent Office. (2016). EP2798015.
[3] World Intellectual Property Organization. (2014). WO2015049275.
[4] United States Patent and Trademark Office. (2014). US20150347532.
